趋化因子CXCL12/CXCR4在小细胞肺癌中的研究进展  

Reserrch progress of chemotactic factor CXCL12/CXCR4 in small cell lung cancer-review

作　　者：赵红丽[1] 王艳[1] ZHAO Hongli;WANG Yan(Department of Medical Oncology,the Affiliated Tumor Hospital of Harbin Medical University,Harbin,Heilongjinag 150040,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江哈尔滨150040

出　　处：《医药前沿》2021年第15期26-28,共3页Journal of Frontiers of Medicine

基　　金：黑龙江省卫生技生委科研课题(2018245)。

摘　　要：小细胞肺癌是肺癌中恶性程度最高的一类亚型,其生物学特点为恶性程度高,预后差。小细胞肺癌目前缺少有效治疗靶点,临床中迫切需要找到新的治疗靶点,改善小细胞肺癌的疗效。趋化因子12(CXCL12)/趋化因子受体4(CXCR4)轴在肿瘤的发生发展中,发挥着重要的作用。CXCR4拮抗剂在小细胞肺癌治疗中显示了一定潜力。本文对CXCR4在小细胞肺癌中的作用及相应靶向药物的研发进行综述。Small cell lung cancer is the most malignant subtype of lung cancer,which is biologically characterized by high degree of malignancy and poor prognosis.Small cell lung cancer currently lacks effective therapeutic targets,and there is an urgent need to find new therapeutic targets to improve the efficacy of small cell lung cancer in clinical practice.The CXCL12/CXCR4 axis plays an important role in the development of tumorigenesis,and CXCR4 antagonists have shown some potential in the treatment of small cell lung cancer.In this paper,the role of CXCR4 in small-cell lung cancer and the development of corresponding targeted drugs are reviewed.

关 键 词：小细胞肺癌 趋化因子 CXCL12 CXCR4 

分 类 号：R734.2[医药卫生—肿瘤]